Denali Therapeutics (DNLI) EBIT: 2017-2024
Historic EBIT for Denali Therapeutics (DNLI) over the last 8 years, with Dec 2024 value amounting to -$129.8 million.
- Denali Therapeutics' EBIT rose 2.06% to -$129.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$487.3 million, marking a year-over-year decrease of 147.76%. This contributed to the annual value of -$487.3 million for FY2024, which is 147.76% down from last year.
- As of Q4 2024, Denali Therapeutics' EBIT stood at -$129.8 million, which was down 5.41% from -$123.2 million recorded in Q3 2024.
- In the past 5 years, Denali Therapeutics' EBIT registered a high of $244.1 million during Q4 2020, and its lowest value of -$132.6 million during Q4 2023.
- For the 3-year period, Denali Therapeutics' EBIT averaged around -$85.4 million, with its median value being -$115.2 million (2023).
- Per our database at Business Quant, Denali Therapeutics' EBIT spiked by 522.59% in 2020 and then crashed by 168.39% in 2024.
- Denali Therapeutics' EBIT (Quarterly) stood at $244.1 million in 2020, then tumbled by 131.60% to -$77.1 million in 2021, then crashed by 36.60% to -$105.3 million in 2022, then dropped by 25.85% to -$132.6 million in 2023, then increased by 2.06% to -$129.8 million in 2024.
- Its EBIT was -$129.8 million in Q4 2024, compared to -$123.2 million in Q3 2024 and -$116.6 million in Q2 2024.